Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

Competing Interests: All authors are employees and shareholders of Baxter BioScience, a manufacturer of biologicals including influenza vaccines. This does not alter the authors' adherence to all the PloS ONE policies on sharing data and materials. Funding: This study was funded by Baxter BioScience. The funders were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript.